Acura Pharmaceuticals files 8-K regarding material asset acquisition and financial obligations

Acura Pharmaceuticals has filed an 8-K disclosing a material definitive agreement, the completion of an asset transaction, and the creation of new financial obligations. The specific terms of the acquisition and the nature of the financial liabilities remain subject to the full exhibit disclosures within the filing.